Promacta

Background

Promacta/Revolade (eltrombopag) is a once-daily oral treatment option for people with chronic Immune Thrombocytopenia (ITP), an autoimmune bleeding disorder. Initially approved by FDA in 2008, it has become a leading treatment for ITP and is currently approved in more than 90 countries worldwide. The approval was later expanded to include Aplastic Anemia, a rare form of bone marrow failure.

“..We are very proud of our discovery contribution to this billion-dollar molecule and best-in-class medicine for a vital medical market. The product has been a big part of our success, driving the company to profitability and generating significant cash flows through the years,” said John Higgins, Chief Executive Officer of Ligand. “We are pleased to work with Royalty Pharma on this deal. They are the world’s largest royalty investor and have extensive experience investing in royalty-bearing assets. We share a common view with Royalty Pharma that owning royalties is a highly efficient and effective way to participate in the potential of the pharmaceutical industry.”

Therapeutic Area

Chronic Immune Thrombocytopenia (ITP)
Aplastic Anemia

Acquisition Date

Mar 2019

Marketer